EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

H. Cheng, K. Ballman, M. Vassilakopoulou, Amylou Dueck, M. M. Reinholz, K. Tenner, J. Gralow, C. Hudis, N. E. Davidson, G. Fountzilas, A. E. McCullough, Beiyun Chen, A. Psyrri, D. L. Rimm, E. A. Perez

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North Central Cancer Treatment Group (NCCTG) N9831 trial. Tissue microarrays were constructed that allowed analysis of 1365 patients randomly assigned to receive chemotherapy alone (Arm A), sequential trastuzumab after chemotherapy (Arm B) and chemotherapy with concurrent trastuzumab (Arm C). Measurement of EGFR was performed using the EGFR antibody, D38B1, on the fluorescence-based AQUA platform. The result was validated using an independent retrospective metastatic breast cancer cohort (n=130). Epidermal growth factor receptor assessed as a continuous (logarithmic transformed) variable shows an association with disease-free survival in Arm C (P=0.009) but not in Arm A or B. High EGFR expression was associated with worse outcome (Hazard ratio (HR)=2.15; 95% CI 1.28-3.60, P=0.004). Validation in a Greek metastatic breast cancer cohort showed an HR associated with high EGFR expression of 1.92 (P=0.0073). High expression of EGFR appears to be associated with decreased benefit from adjuvant concurrent trastuzumab. Since other treatment options exist for HER2-driven tumours, further validation of these data may select patients for alternative or additive therapy.

Original languageEnglish (US)
Pages (from-to)1065-1071
Number of pages7
JournalBritish Journal of Cancer
Volume111
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Epidermal Growth Factor Receptor
Neoplasms
Therapeutics
Drug Therapy
Breast Neoplasms
Trastuzumab
Antibodies
Disease-Free Survival
Fluorescent Antibody Technique
Fluorescence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cheng, H., Ballman, K., Vassilakopoulou, M., Dueck, A., Reinholz, M. M., Tenner, K., ... Perez, E. A. (2014). EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. British Journal of Cancer, 111(6), 1065-1071. https://doi.org/10.1038/bjc.2014.442

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. / Cheng, H.; Ballman, K.; Vassilakopoulou, M.; Dueck, Amylou; Reinholz, M. M.; Tenner, K.; Gralow, J.; Hudis, C.; Davidson, N. E.; Fountzilas, G.; McCullough, A. E.; Chen, Beiyun; Psyrri, A.; Rimm, D. L.; Perez, E. A.

In: British Journal of Cancer, Vol. 111, No. 6, 2014, p. 1065-1071.

Research output: Contribution to journalArticle

Cheng, H, Ballman, K, Vassilakopoulou, M, Dueck, A, Reinholz, MM, Tenner, K, Gralow, J, Hudis, C, Davidson, NE, Fountzilas, G, McCullough, AE, Chen, B, Psyrri, A, Rimm, DL & Perez, EA 2014, 'EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.', British Journal of Cancer, vol. 111, no. 6, pp. 1065-1071. https://doi.org/10.1038/bjc.2014.442
Cheng, H. ; Ballman, K. ; Vassilakopoulou, M. ; Dueck, Amylou ; Reinholz, M. M. ; Tenner, K. ; Gralow, J. ; Hudis, C. ; Davidson, N. E. ; Fountzilas, G. ; McCullough, A. E. ; Chen, Beiyun ; Psyrri, A. ; Rimm, D. L. ; Perez, E. A. / EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. In: British Journal of Cancer. 2014 ; Vol. 111, No. 6. pp. 1065-1071.
@article{e155b6df9ef74d3bb065fe86d83690d3,
title = "EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.",
abstract = "Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North Central Cancer Treatment Group (NCCTG) N9831 trial. Tissue microarrays were constructed that allowed analysis of 1365 patients randomly assigned to receive chemotherapy alone (Arm A), sequential trastuzumab after chemotherapy (Arm B) and chemotherapy with concurrent trastuzumab (Arm C). Measurement of EGFR was performed using the EGFR antibody, D38B1, on the fluorescence-based AQUA platform. The result was validated using an independent retrospective metastatic breast cancer cohort (n=130). Epidermal growth factor receptor assessed as a continuous (logarithmic transformed) variable shows an association with disease-free survival in Arm C (P=0.009) but not in Arm A or B. High EGFR expression was associated with worse outcome (Hazard ratio (HR)=2.15; 95{\%} CI 1.28-3.60, P=0.004). Validation in a Greek metastatic breast cancer cohort showed an HR associated with high EGFR expression of 1.92 (P=0.0073). High expression of EGFR appears to be associated with decreased benefit from adjuvant concurrent trastuzumab. Since other treatment options exist for HER2-driven tumours, further validation of these data may select patients for alternative or additive therapy.",
author = "H. Cheng and K. Ballman and M. Vassilakopoulou and Amylou Dueck and Reinholz, {M. M.} and K. Tenner and J. Gralow and C. Hudis and Davidson, {N. E.} and G. Fountzilas and McCullough, {A. E.} and Beiyun Chen and A. Psyrri and Rimm, {D. L.} and Perez, {E. A.}",
year = "2014",
doi = "10.1038/bjc.2014.442",
language = "English (US)",
volume = "111",
pages = "1065--1071",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

AU - Cheng, H.

AU - Ballman, K.

AU - Vassilakopoulou, M.

AU - Dueck, Amylou

AU - Reinholz, M. M.

AU - Tenner, K.

AU - Gralow, J.

AU - Hudis, C.

AU - Davidson, N. E.

AU - Fountzilas, G.

AU - McCullough, A. E.

AU - Chen, Beiyun

AU - Psyrri, A.

AU - Rimm, D. L.

AU - Perez, E. A.

PY - 2014

Y1 - 2014

N2 - Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North Central Cancer Treatment Group (NCCTG) N9831 trial. Tissue microarrays were constructed that allowed analysis of 1365 patients randomly assigned to receive chemotherapy alone (Arm A), sequential trastuzumab after chemotherapy (Arm B) and chemotherapy with concurrent trastuzumab (Arm C). Measurement of EGFR was performed using the EGFR antibody, D38B1, on the fluorescence-based AQUA platform. The result was validated using an independent retrospective metastatic breast cancer cohort (n=130). Epidermal growth factor receptor assessed as a continuous (logarithmic transformed) variable shows an association with disease-free survival in Arm C (P=0.009) but not in Arm A or B. High EGFR expression was associated with worse outcome (Hazard ratio (HR)=2.15; 95% CI 1.28-3.60, P=0.004). Validation in a Greek metastatic breast cancer cohort showed an HR associated with high EGFR expression of 1.92 (P=0.0073). High expression of EGFR appears to be associated with decreased benefit from adjuvant concurrent trastuzumab. Since other treatment options exist for HER2-driven tumours, further validation of these data may select patients for alternative or additive therapy.

AB - Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North Central Cancer Treatment Group (NCCTG) N9831 trial. Tissue microarrays were constructed that allowed analysis of 1365 patients randomly assigned to receive chemotherapy alone (Arm A), sequential trastuzumab after chemotherapy (Arm B) and chemotherapy with concurrent trastuzumab (Arm C). Measurement of EGFR was performed using the EGFR antibody, D38B1, on the fluorescence-based AQUA platform. The result was validated using an independent retrospective metastatic breast cancer cohort (n=130). Epidermal growth factor receptor assessed as a continuous (logarithmic transformed) variable shows an association with disease-free survival in Arm C (P=0.009) but not in Arm A or B. High EGFR expression was associated with worse outcome (Hazard ratio (HR)=2.15; 95% CI 1.28-3.60, P=0.004). Validation in a Greek metastatic breast cancer cohort showed an HR associated with high EGFR expression of 1.92 (P=0.0073). High expression of EGFR appears to be associated with decreased benefit from adjuvant concurrent trastuzumab. Since other treatment options exist for HER2-driven tumours, further validation of these data may select patients for alternative or additive therapy.

UR - http://www.scopus.com/inward/record.url?scp=84908386493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908386493&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.442

DO - 10.1038/bjc.2014.442

M3 - Article

C2 - 25117817

AN - SCOPUS:84908386493

VL - 111

SP - 1065

EP - 1071

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -